The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety

@article{Jones2018ThePA,
  title={The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety},
  author={J. Jones and A. Bisaga and Verena E Metz and J. Manubay and S. Mogali and R. Ciccocioppo and Gabriela Madera and M. Doernberg and S. Comer},
  journal={Journal of Psychoactive Drugs},
  year={2018},
  volume={50},
  pages={390 - 401}
}
  • J. Jones, A. Bisaga, +6 authors S. Comer
  • Published 2018
  • Medicine
  • Journal of Psychoactive Drugs
  • ABSTRACT Possibly through its effects on glia, the peroxisome proliferator-activated gamma receptor (PPARγ) agonist pioglitazone (PIO) has been shown to alter the effects of heroin in preclinical models. Until now, these results have not been assessed in humans. Heroin-dependent participants were randomized to either active (45 mg, n = 14) or placebo (0 mg, n = 16) PIO maintenance for the duration of the three-week study. After stabilization on buprenorphine (8 mg), participants began a two… CONTINUE READING
    9 Citations

    Topics from this paper

    Clinical Trials for Opioid Use Disorder.
    Craving and opioid use disorder: A scoping review.
    • 4
    Potential of Glial Cell Modulators in the Management of Substance Use Disorders
    Glial neuroimmune signaling in opioid reward
    • 3

    References

    SHOWING 1-10 OF 75 REFERENCES
    Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential
    • 17
    Comparison of Intravenous Buprenorphine and Methadone Self-Administration by Recently Detoxified Heroin-Dependent Individuals
    • 46
    • PDF
    PPARc Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission
    • 27
    • PDF
    PPARγ Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission
    • 16
    The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid‐dependent volunteers
    • 38